Esperion's bempedoic acid is continuing its roll, lowering LDL cholesterol in patients with atherosclerosis.

AstraZeneca has opened its new South San Francisco R&D facility, bundling five sites into a single unit at the heart of California’s biotech cluster.

The planned IPO will give Verrica the money to take a treatment for viral skin infection molluscum through phase 3 and onto the market.

The cash equips Lava to advance bispecific engagers of γδ T cells, a small subgroup of lymphocytes involved in natural and induced immunity to cancer.

Takeda's $62 billion acquisition of Shire added $31 billion to its debt load. Now, it's looking to cut costs where it can.

A team of scientists clarified the role of the protein LRRK2 in tuberculosis, suspecting that it behaves similarly in Parkinson's.

Allergan acquired an NMDA receptor modulator discovered by Aptinyx, planning to pair it with its rapastinel depression therapy currently in phase 3.

Early data suggest the new batch of therapies is at least as effective as its predecessor, clearing a potential pitfall on Spark’s path to market.

The strategic partnership tasks Evotec with applying its R&D toolkit to the discovery of solid tumor drugs that Celgene will then pick up and advance.